Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer

被引:102
作者
Eggemann, Holm [1 ]
Ignatov, Tanja [1 ]
Burger, Elke [2 ]
Kantelhardt, Eva Johanna [3 ]
Fettke, Franziska [1 ]
Thomssen, Christoph [3 ]
Costa, Serban Dan [1 ]
Ignatov, Atanas [1 ]
机构
[1] Univ Magdeburg, Dept Obstet & Gynecol, D-39108 Magdeburg, Germany
[2] Univ Magdeburg, Inst Biometry & Med Informat, D-39108 Magdeburg, Germany
[3] Univ Halle Wittenberg, Dept Gynecol, D-06108 Halle, Saale, Germany
关键词
HER2; HER2 2+; score; breast cancer; ADJUVANT TRASTUZUMAB; TAMOXIFEN RESISTANCE; GENE AMPLIFICATION; AMERICAN-SOCIETY; HER-2/NEU; RECOMMENDATIONS; HERCEPTEST; THERAPY;
D O I
10.1530/ERC-15-0335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2) is associated with poor prognosis in breast cancer and predicts response to anti-HER2 therapy in breast cancer. The prognostic relevance of moderate expression of HER2 is unclear. Data of 9872 patients with primary nonmetastatic breast cancer from the cancer registries of Magdeburg and Halle, Germany, were analyzed retrospectively. A total of 5907 patients with complete data sets including follow-up were eligible for analysis. HER2 status was determined as recommended by international guidelines. Of 5907 patients investigated, 5023 (68.4%) had HER2 0 and 1+ expression and 884 (12.0%) had HER2 (2+)/HER2-expression. Patients with hormone receptor positive (HRC) and HER2 (2+) tumors had a shorter median disease-free survival (DFS; P<0.0001) and breast cancer specific survival (BCSS; P=0.019) than HRC patients with HER2 (0/1+) tumors. Among patients with HR- breast cancer there was no significant difference between HER2 (2+) and HER2 (0/1+) tumors. In multivariate analysis after adjustment for other prognostic factors, HER2 (2+) status remained an unfavorable prognostic factor for DFS (hazard ratio (HR) =1.217, 95% CI=1.052-1.408; P=0.008) but not for BCSS (HR=1.045, 95% CI=0.926-1.178; P=0.474). The HER2 (2+) status is an unfavorable prognostic factor for survival of patients with HRC breast cancer. The impact of anti-HER2 therapy in this group of patients should be evaluated.
引用
收藏
页码:725 / 733
页数:9
相关论文
共 24 条
[1]   THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].
AKIYAMA, T ;
SUDO, C ;
OGAWARA, H ;
TOYOSHIMA, K ;
YAMAMOTO, T .
SCIENCE, 1986, 232 (4758) :1644-1646
[2]   Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive for false-negative immunohistochemistry? [J].
Barrett, Ciara ;
Magee, Hilary ;
O'Toole, Denise ;
Daly, Sinead ;
Jeffers, Michael .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (06) :690-693
[3]   HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer [J].
Berry, DA ;
Muss, HB ;
Thor, AD ;
Dressler, L ;
Liu, ET ;
Broadwater, G ;
Budman, DR ;
Henderson, IC ;
Barcos, M ;
Hayes, D ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3471-3479
[4]  
Camp RL, 2003, CANCER RES, V63, P1445
[5]   C-ERBB-3 AND C-ERBB-2 PROTEIN EXPRESSION IN NODE-NEGATIVE BREAST-CARCINOMA - AN IMMUNOCYTOCHEMICAL STUDY [J].
GASPARINI, G ;
GULLICK, WJ ;
MALUTA, S ;
DALLAPALMA, P ;
CAFFO, O ;
LEONARDI, E ;
BORACCHI, P ;
POZZA, F ;
LEMOINE, NR ;
BEVILACQUA, P .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (01) :16-22
[6]   HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials [J].
Gennari, Alessandra ;
Sormani, Maria Pia ;
Pronzato, Paolo ;
Puntoni, Matteo ;
Colozza, Mariantonietta ;
Pfeffer, Ulrich ;
Bruzzi, Paolo .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01) :14-20
[7]   Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer [J].
Gilcrease, Michael Z. ;
Woodward, Wendy A. ;
Nicolas, Marlo M. ;
Corley, Lynda J. ;
Fuller, Gregor N. ;
Esteva, Francisco J. ;
Tucker, Susan L. ;
Buchholz, Thomas A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (05) :759-767
[8]   Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J].
Goldhirsch, A. ;
Winer, E. P. ;
Coates, A. S. ;
Gelber, R. D. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2013, 24 (09) :2206-2223
[9]   HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? [J].
Iorfida, M. ;
Dellapasqua, S. ;
Bagnardi, V. ;
Cardillo, A. ;
Rotmensz, N. ;
Mastropasqua, M. G. ;
Bottiglieri, L. ;
Goldhirsch, A. ;
Viale, G. ;
Colleoni, M. .
ANNALS OF ONCOLOGY, 2012, 23 (05) :1371-1372
[10]   Specificity of HercepTest in determining HER-2/neu status of breast cancers using the united states food and drug administration-approved scoring system [J].
Jacobs, TW ;
Gown, AM ;
Yaziji, H ;
Barnes, MJ ;
Schnitt, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :1983-1987